This list is an analysis based on recent market events. It's not an investment recommendation.
About
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
The current price of RGMP is $0 USD — it has decreased by -98.31% in the past 24 hours. Watch Regnum stock price performance more closely on the chart.
What is Regnum stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Regnum stocks are traded under the ticker RGMP.
Is Regnum stock price growing?▼
RGMP stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Regnum has showed a +0% increase.
What were Regnum earnings last quarter?▼
RGMP earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regnum revenue for the last year?▼
Regnum revenue for the last year amounts to 0 USD.
What is Regnum net income for the last year?▼
RGMP net income for the last year is -269,830 USD.
How many employees does Regnum have?▼
As of April 01, 2026, the company has 1 employees.